September 2026
The orphan disease biomarkers market expands with advancements in genomics, proteomics, and bioinformatics for rare conditions.
September 2026
The parkinsons disease biomarkers market size reached USD 1.54 billion in 2026, with leading parkinsons disease biomarkers market companies including F. Hoffmann-La Roche Ltd., Bio-Rad Laboratories, Thermo Fisher Scientific, Abbott Laboratories.
July 2025
The global in-vitro inflammatory bowel disease diagnostics market size was valued at USD 1.74 billion in 2024 and is expected to hit around USD 3.02 billion by 2034, at a CAGR of 5.64%.
September 2026
The infectious respiratory disease diagnostics market size was USD 60.62 billion in 2026, with leading infectious respiratory disease diagnostics market players including F. Hoffmann - La Roche, Thermo Fisher Scientific, Danaher (Cepheid), Abbott LaboratoriesÂ
September 2026
The global digital biomarkers market size calculated at USD 6.19 billion in 2026 and is projected to hit around USD 36.98 billion by 2035 with a CAGR of 22.05%.
September 2026
The global orphan drugs market size was surpass to USD 242.97 billion in 2026 and is projected to reach around USD 676.59 billion by 2035 with a CAGR of 12.07%.
September 2026
The global sickle cell disease treatment market size is predicted to hit around USD 15.81 billion by 2035 from USD 4.35 billion in 2026 with a CAGR of 15.48%.
September 2026
The rare disease small-batch CDMO market is expanding with demand for specialized manufacturing of orphan drugs and niche therapies.
September 2026
The global inflammatory bowel disease treatment market size is projected to hit around USD 32.46 billion by 2035 from USD 22.38 billion in 2025, with a CAGR of 3.79%.
September 2026
The global predictive biomarkers market size is valued at USD 34.32 billion in 2026 and is predicted to hit around USD 155.53 billion by 2035, at a CAGR of 18.34%.
September 2026
The global infectious disease molecular diagnostics market size is estimated to hit around USD 63.37 billion by 2034 with a CAGR of 3.25% from 2026 to 2034.
September 2026
The global sexually transmitted diseases diagnostics market size is estimated to hit around USD 21.44 billion by 2034 from USD 12.26 billion in 2026, with a CAGR of 7.24%.
September 2026
The global biomarkers market size was valued at USD 107.90 billion in 2026 and is expected to hit around USD 355.72 billion by 2035 with a CAGR of 14.21%.
September 2026
The lyme disease diagnostic devices market size accounted for USD 2.97 billion in 2026 and is predicted to hit around USD 4.79 billion by 2035, with a CAGR of 5.44%.
September 2026
The cns biomarkers market size was USD 8.81 billion in 2026, with leading cns biomarkers market players including F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific, Bio-Rad Laboratories, Quanterix Corporation.
September 2026
The global periodontal disease treatment market size was evaluated at USD 3.17 billion in 2026 and is predicted to hit around USD 6.23 billion by 2035, growing at a CAGR of 7.80%.
September 2026
The global enteric disease testing market size was evaluated at USD 4.58 billion in 2026 and is predicted to hit around USD 8.09 billion by 2035, growing at a CAGR of 6.52%.
September 2026
The global inflammatory disease market size was evaluated at USD 133.50 billion in 2026 and is predicted to hit around USD 241.34 billion by 2035, growing at a CAGR of 6.80%.
September 2026
The global Alzheimers disease diagnostics market size was evaluated at USD 10.42 billion in 2026 and is predicted to hit around USD 26.21 billion by 2035, growing at a CAGR of 10.80%.
September 2026
The global Huntingtons disease market size was evaluated at USD 1.66 billion in 2026 and is predicted to hit around USD 6.48 billion by 2035, growing at a CAGR of 17.20%.
September 2026
The global cardiac biomarkers market size reached USD 27.86 billion in 2026 and is projected to surpass around USD 82.99 billion by 2034, with a remarkable CAGR of 14.62%.
September 2026
The neurological biomarkers market size reached USD 11.66 billion in 2026 and is projected to surpass around 34.02 billion by 2035, with a solid CAGR of 12.67%.
August 2026
The infectious disease vaccines market size reached USD 41.60 billion in 2026, with leading infectious disease vaccines market companies including Pfizer, Moderna, Johnson & Johnson (Janssen), GlaxoSmithKline (GSK).
August 2026
The end stage renal disease market was valued at USD 174.43 billion in 2026, with end stage renal disease market leading companies including Nipro Corp., Fresenius Medical Care AG & Co. KGaA, Baxter International, Inc.,Medtronic Plc.
August 2026
The global cancer biomarkers market size was estimated at USD 15.58 billion in 2025 and is projected to hit around USD 47.14 billion by 2035 with a CAGR of 11.71%.
June 2026
The global celiac disease treatment market size is evaluated at USD 784.59 million in 2025 and is predicted to hit around USD 2,400.49 million by 2035, growing at a CAGR of 11.83%.
June 2026
The global circulating biomarkers market size is estimated to hit around USD 15.62 billion by 2035 increasing from USD 5.17 billion in 2025, with a CAGR of 11.69%.
June 2026
The global non-alcoholic fatty liver disease (NAFLD) drug market size is estimated to hit around USD 35.10 billion by 2035 from USD 23.04 billion in 2026, with a CAGR of 4.79%.
June 2026
The global minimal residual disease (MRD) testing market size is estimated to hit around USD 5.19 billion by 2035 increasing from USD 1.70 billion in 2025, with a CAGR of 11.81%.
June 2026
The global chronic disease management market size was estimated at USD 6.61 billion in 2025 and is expected to hit around USD 23.18 billion by 2035, growing at a CAGR of 13.37% from 2026 to 2035.
+1 650 460 3308
+61 485 981 310 +91 87933 22019
sales@precedenceresearch.com